Questions across 4 calls

Vivek Agarwal

Citi Group

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited CC-Feb26.pdf · 2026-02-13

Yes, thanks for taking the question. My question is on Germany; you have highlighted that there is some disruption from one of your suppliers of the product . So, I just want to understand whether the disruption is fully there in the numbers or is it like it is partly reflected or, for example, this quarter you can see the sales dip. Thank you.

Got it, sir. Sir, one question I have on U.S. right. So, for quite some time, actually, if you look, your sales numbers are largely hovering somewhere around $33, $35 million. Now, if you look at both of your facilities, maybe facilities are clear. So, when I think you are expecting a meaningful jump in your sales or any possibility that it can go up to $45, $50?

Torrent Pharmaceuticals Limited CC-Mar25.pdf · 2025-05-20

Yes, thanks for the opportunity. So , my question is related to Bra zil. If you can help us understand, sir, how many MRs or the salesforce that we have at this point of time? Have you increased the number of people on ground in the last few years? And how to look, let's say, over the next two, three years, as far as the number of people?

Understood, thank you. And if we look at the MR productivity, right, so I don't have any clarity what kind of the productivity that is there in Brazil. So, if you can help us understand basically how far you are from the normalized level of productivity in Brazil or is it, for example , the productivity already optimal? So, how we should think from that perspective?

Concord Biotech Limited

Concord Biotech Limited CC-Mar24.pdf · 2024-05-28

Hi. Thanks for taking the question. Ankur just one question on Limbasi facility as you have indicated that you are adding new customers etc. So what is the current capacity utilization of this facility and what is the current revenue contribution? So is it really contributing in terms of revenue new numbers, etc?

But how much it is contributing in terms of revenue. So if the Limbasi facility utilization has moved up. So then it should have driven especially the APIs somewhat right but that is also not reflecting?

Concord Biotech Limited CC-Dec23.pdf · 2024-02-09

Hi, thanks for the opportunity. So, in the last 9 months, we have grown, our top line has grown by around close to 20%, right? So, any updated guidance for, let's say, how to look at FY '24 and '25 numbers in terms of growth, though we continue to maintain around 25% kind of long term guidance, but it would be super helpful if we can share some near term trends as well? Thank you.

Thanks, Ankur. And would you like to share how the pricing has behaved for the top four, five products, especially in the API segment? And what is your contribution of the top five products as a percentage of revenue has moved over the last 9 months? Thank you.